Published studies demonstrated that deguelin inhibits Akt and downstream mammalian target or rapamycin (mTOR) signaling [7], [12], considering that activation of Akt contributes to HNSCC progression [24], we then examined deguelin’s role on Akt signaling. This evidence concerns the gene AKT1 and head and neck squamous cell carcinoma.